Mentari Therapeutics Begins Trading as MTRI

The merger of Mentari and InMed Pharmaceuticals closed, with the combined company listed on the Nasdaq Capital Market.

Updated on Nov. 9, 2026 in Healthcare

Mentari Therapeutics Begins Trading as MTRI

Mentari Therapeutics completed its merger with InMed Pharmaceuticals, and its shares began trading on the Nasdaq Capital Market under the ticker MTRI. The combined company is based in Waltham, Massachusetts, and operates as Mentari Therapeutics, Inc.

Why it matters

The merger and accompanying financings give the combined company a larger capital base to advance its clinical programs, including Phase 1 development of MT-001 and the MT-002 bispecific antibody program. The transaction also brings a new public listing for a Waltham-headquartered drug developer.

Mentari raised approximately $490 million in gross proceeds through private placements led by Fairmount, including $50.0 million in converted convertible notes plus accrued interest. Roughly 58.3 million common shares and equivalents are outstanding following the reverse stock split, private placements, and merger, though the source does not report trading performance since listing.

The players

Mentari Therapeutics, Inc.

A Waltham, Massachusetts-based drug developer formed through the merger of Mentari and InMed Pharmaceuticals, focused on neurology therapeutics including migraine treatments.

Fairmount

A life sciences investment firm that led the private placement financings completed immediately before the merger closed.

Todd Shegog

A finance executive appointed to Mentari's Board of Directors who serves as Chair of the Audit Committee.

The details

The combined company, Mentari Therapeutics, Inc., was formed when InMed Pharmaceuticals completed the merger, with Mentari completing private financings led by Fairmount immediately before the closing. Todd Shegog joined the board and serves as Chair of the Audit Committee, while Phase 1 development of MT-001 continues and MT-002, an investigational bispecific antibody targeting PACAP and CGRP, is advancing; Mentari's lead programs were discovered by Paragon.

Timeline

  1. November 9, 2026: Merger closed and shares began trading on Nasdaq as MTRI.

  2. October 1, 2026: InMed's registration statement was declared effective by the SEC.

  3. Q1 2027: MT-002 regulatory filing is planned.

  4. Mid-2027: Initial MT-001 Phase 1 data is expected.

Market Landscape

The transaction follows the reverse-merger route that clinical-stage biotechs have used to reach public markets without a traditional IPO. Mentari's combined financing and listing place it among smaller-cap neurology developers competing for investor capital.

For Waltham residents and investors tracking the sector, the listing creates a new publicly traded option in local neurology drug development. Readers following the stock should note that the source does not report post-listing performance.

The takeaway

The completed merger and financing give Mentari a funded public platform for its migraine programs over the next 12 to 18 months. Watch for the MT-002 regulatory filing in early 2027 and initial MT-001 Phase 1 data in mid-2027 as the next concrete milestones.

What happens next

Initial MT-002 regulatory filing is planned for Q1 2027, with initial MT-001 Phase 1 data expected in mid-2027 and MT-002 initial data by year-end 2027.

Further reading

For more on the regional sector, explore Healthcare coverage tied to Waltham.